News
SGMOQ
0.175
+6.06%
0.010
Sangamo Concludes Section 363 Asset Sales in Bankruptcy
TipRanks · 3d ago
Press Release: Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones
Dow Jones · 4d ago
Sangamo Therapeutics Reports Post-Bankruptcy Operating Developments
TipRanks · 4d ago
Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones
Barchart · 4d ago
Weekly Report: what happened at SGMOQ last week (0803-0807)?
Weekly Report · 6d ago
Weekly Report: what happened at SGMOQ last week (0727-0731)?
Weekly Report · 08/03 09:02
Weekly Report: what happened at SGMOQ last week (0720-0724)?
Weekly Report · 07/27 09:02
Sangamo Therapeutics Advances Bankruptcy Asset Sale Process
TipRanks · 07/20 20:54
Weekly Report: what happened at SGMOQ last week (0713-0717)?
Weekly Report · 07/20 09:02
Weekly Report: what happened at SGMOQ last week (0706-0710)?
Weekly Report · 07/13 09:02
Weekly Report: what happened at SGMOQ last week (0629-0703)?
Weekly Report · 07/06 09:02
Sangamo Shares Shift to OTC Market Amid Bankruptcy
TipRanks · 07/01 20:50
Weekly Report: what happened at SGMOQ last week (0622-0626)?
Weekly Report · 06/29 09:02
Sangamo Bankruptcy Puts Gene Therapy Platforms In Play, Eli Lilly And Astellas Circle
Benzinga · 06/23 17:46
Sangamo files for restructuring, plans asset sales to Lilly, Astellas
TipRanks · 06/23 16:21
Sangamo Therapeutics Initiates Chapter 11 and Asset Sales
TipRanks · 06/23 14:06
Sangamo Therapeutics Files For Chapter 11 Bankruptcy, Secures Up To $30M In Debtor-In-Possession Financing; Launches Court-Supervised Asset Sale Process With Eli Lilly And Astellas As Stalking Horse Bidders For Key Gene Therapy, Genome Editing, And Fabry Disease Assets; Expects Restructuring To Result In Elimination Of About 51 Roles In U.S., Or About 40% Of Company's Workforce
Benzinga · 06/23 12:55
Sangamo Therapeutics files for chapter 11 bankruptcy
Seeking Alpha · 06/23 10:06
Weekly Report: what happened at SGMO last week (0615-0619)?
Weekly Report · 06/22 09:03
Weekly Report: what happened at SGMO last week (0608-0612)?
Weekly Report · 06/15 09:03
More
Webull provides a variety of real-time SGMOQ stock news. You can receive the latest news about Sangamo Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About SGMOQ
Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.